A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The study is designed to assess efficacy of a finitie treatment in Chronic Hepatitis B
patients who had stable treatment of NAs for ≧ 2 years， which is compared hepalatide in
combination with Pegylated Interferon + TAF with Pegylated Interferon +TAF. Subjects will be
randomly assigned to the hepalatide or placebo groups , 15 subjects in each group . Subjects
will receive hepalatide+Pegylated Interferon +TAF treatment for 48 weeks or placebo
+PegylatedInterferon +TAF treatment for 48 weeks , Then, stopping all treatments and followed
with further 24 weeks follow-up.